Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohsin Salih

Interventional Cardiology Alton, IL Medical Doctor

NPI 1326488594 CMS profile 333018

2 Memorial Dr Ste 122, Alton, IL 62002

Open in the dashboard

General payments

$10,149

86 records reported · program years 2019–2025

Research payments

$459

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohsin Salih of Alton, IL is reported in the CMS Open Payments database as having received $10,149 across 86 general payments and $459 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,351 22
2024 General $785 6
2024 Research $459 3
2023 General $5,927 42
2022 General $1,694 13
2021 General $280 2
2019 General $111 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohsin Salih
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Mohsin Salih were reported at $1,351. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Mohsin Salih Interventional Cardiology median Middle half National median
2019 $111 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $280 $677 $233–$1,827 $132
2022 $1,694 $978 $333–$2,724 $149
2023 $5,927 $1,136 $382–$2,986 $160
2024 $785 $1,181 $395–$3,326 $164
2025 $1,351 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,606 22 payments
  2. Abiomed $2,409 19 payments
  3. Edwards Lifesciences Corporation $1,703 10 payments
  4. Medtronic, Inc. $1,331 10 payments
  5. Boston Scientific Corporation $745 6 payments
  6. Asahi Intecc USA, Inc. $737 5 payments
  7. Teleflex LLC $151 1 payment
  8. Philips Electronics North America Corporation $114 1 payment
  9. Janssen Pharmaceuticals, Inc $111 1 payment
  10. Penumbra, Inc. $98 1 payment
  11. Other $144 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,056 71 payments
  2. Travel and Lodging $4,092 14 payments
  3. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. OPTIS $1,921 17 payments
  2. Impella $1,303 8 payments
  3. COREVALVE EVOLUT R $1,256 8 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $685 8 payments
  5. ASAHI PTCA Guide Wire $370 3 payments
  6. PERIPHERAL VASCULAR $368 2 payments
  7. General - Vascular Access $311 2 payments
  8. Xience Skypoint $154 1 payment
  9. GUIDELINER $151 1 payment
  10. DRAGONFLY OPSTAR $149 1 payment
  11. Other $1,192 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $459 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

458

Median for Interventional Cardiology: 2,236

Drug cost

$26,070

Median for Interventional Cardiology: $380,412

Branded share of claims

16.6%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 20 $14,930
Jardiance Empagliflozin Brand 11 $7,586
Metoprolol Succinate Generic 59 $649
Hydralazine Hcl Generic 17 $348
Atorvastatin Calcium Generic 45 $335
Rosuvastatin Calcium Generic 37 $315
Clopidogrel Clopidogrel Bisulfate Brand 27 $301
Spironolactone Generic 26 $276
Losartan Potassium Generic 39 $271
Furosemide Generic 61 $269

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$62,531

Medicare's payments for the services billed

Medicare patients

299

Average age 73

Services billed

678

128 women, 171 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 69%
Diabetes 48%
Heart failure 48%
Arthritis 48%
Atrial fibrillation 37%
Chronic kidney disease 36%
COPD 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

89 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record